Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Cancer Research UK to use Astra Zeneca’s AZD1775 in head and neck cancer trial UK researchers are all set to launch an early-stage trial to evaluate an experimental drug from Astra Zeneca’s for improving the treatment of head and neck cancer. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Cancer Research UK to use Astra Zeneca’s AZD1775 in head and neck cancer trial
By PBR Staff Writer
UK researchers are all set to launch an early-stage trial to evaluate an experimental drug from Astra Zeneca’s for improving the treatment of head and neck cancer.
Contract Research & Services > Clinical Trials > News
Cytokinetics’ ALS treatment tirasemtiv fails to meet primary endpoint in phase 3 study
Cytokinetics has announced that international phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) has did not meet the primary endpoint.
Contract Research & Services > Clinical Trials > News

Contract Research

Cue Biopharma forms research collaboration and signs license deal with Merck
Immunotherapy company Cue Biopharma has entered into a strategic research collaboration and license agreement with Merck.
Contract Research & Services > Contract Research > News
Merck cholesterol drug reduces heart risk by 9% in study
By PBR Staff Writer
Merck’s cardiovascular treatment anacetrapib has reduced the risk of major coronary events in the REVEAL study.
Contract Research & Services > Clinical Trials > News

Contract Services

Arvinas, Genentech expand license agreement for Protac
Arvinas has expanded its ongoing license agreement with Genentech for the development of new therapeutics using its novel PROTAC technology.
Contract Research & Services > Contract Services > News
Xenetic signs sublicense deal related to PolyXen technology with Baxalta
Xenetic Biosciences has entered into a Right to Sublicense Agreement with Baxalta, Baxalta, and Baxalta (collectively, with their affiliates, “Baxalta”), wholly-owned subsidiaries of Shire.
Contract Research & Services > Contract Services > News